Interim results for the six months ended 30 june 2023

29 september 2023 biodexa pharmaceuticals plc (“ biodexa ” or the “company”) interim results for the six months ended 30 june 202 3 biodexa pharmaceuticals plc (nasdaq: bdrx), a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain, announces its unaudited interim results for the six months ended 30 june 2023 which will also be made available on the company's website at www.biodexapharma.com. operational highlights the company announced the following in the six months ended 30 june 2023: approval by the data safety monitoring board to escalate the dose of mtx110 in recurrent glioblastoma (rgbm) to 90Μm, the expected optimal therapeutic dose.
BDRX Ratings Summary
BDRX Quant Ranking